4.2 Article

Insomnia in Patients With Depression: A STAR*D Report

期刊

CNS SPECTRUMS
卷 15, 期 6, 页码 394-404

出版社

CAMBRIDGE UNIV PRESS
DOI: 10.1017/S1092852900029266

关键词

-

资金

  1. Bristol-Myers Squibb
  2. Eli Lilly
  3. Takeda
  4. Agency for Healthcare Research and Quality
  5. National Institute of Mental Health (NIMH)
  6. Novartis
  7. M-3 Corporation
  8. Abbott
  9. Alkermes
  10. Aspect Medical Systems
  11. AstraZeneca
  12. Cephalon
  13. Forest Pharmaceuticals
  14. Ganeden
  15. GlaxoSmithKline
  16. Johnson Johnson
  17. Lichtwer Pharma GmbH
  18. Lorex
  19. National Alliance for Research in Schizophrenia and Depression (NARSAD)
  20. National Center for Complementary and Alternative Medicine
  21. National Institute on Drug Abuse (NIDA)
  22. NIMH
  23. Organon
  24. Pamlab
  25. Pfizer
  26. Pharmavite
  27. Roche
  28. sanoffaventis
  29. Shire
  30. Solvay
  31. Synthelabo
  32. Wyeth
  33. Stanley Medical Research Institute
  34. Society of Biological Psychiatry
  35. Corcept
  36. Cyberonics
  37. Merck
  38. NIDA
  39. NARSAD
  40. Pharmacia Upjohn
  41. Predix
  42. Targacept
  43. NIMH, Notional Institutes of Health [NO1MH90003]
  44. NATIONAL INSTITUTE OF MENTAL HEALTH [N01MH090003] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Introduction: Insomnia symptoms, which are common in depression, have a significant impact on function and quality of life. However, little is known about the prevalence and associated features of insomnia symptoms in representative treatment-seeking patients with depression. Methods: Data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial were analyzed. STAR*D recruited 3,743 adult outpatients diagnosed with nonpsychotic major depressive disorder (MDD) from primary (n=18) and psychiatric care (n=23) clinics across the United States. Baseline sociodemographic and clinical features were compared between those with insomnia symptoms (84.7%) and those without (15.3%). Results: The most common presentation was the simultaneous presence of sleep onset, mid-nocturnal, and early morning insomnia symptoms (27.1%). Of these three types of insomnia symptoms, mid-nocturnal insomnia symptoms were the most commonly found alone (13.5%) and in combination with one or more other types (82.3%). Insomnia symptoms were associated with several indicators of a more severe depressive illness. Only a small proportion of participants with insomnia symptoms were receiving treatment for sleep disturbances at study initiation, and the vast majority of those receiving treatment still reported having insomnia symptoms. Conclusion: In outpatients who seek treatment for nonpsychotic MDD in typical clinical settings, insomnia symptoms are very common, undertreated, and indicative of a more severe depression. CNS Spectr. 2010;15(6):394-404.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据